Associate Professor of Medicine
Member of the Duke Cancer Institute
Email address
michael.harrison@duke.edu
Education and Training
- residency, Medicine, Tulane University, 2004 - 2007
- M.D., Tulane University, 2004
Grants
- Propella: Intramuscular abiraterone decanoate for metastatic prostate cancer PRL-02
- ODYSSEY Registry for Renal Cell Carcinoma
- Title A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (Substudy U03A)
- A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCIN
- A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03):
- A randomized, open-label, multicenter, Phase 2b study to evaluate physical function, including balance and daily activity, in participants with castration-resistant prostate cancer treated with darolutamide or enzalutamide
- STUDY/PROTOCOL TITLE AND PROTOCOL NUMBER: "A Phase II, Open-label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men with High Risk Prostate Cancer"; XL184-IST64
- A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unr
- A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint i
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
- Phase II Single Arm Study of Gemcitabine and Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer
- A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
- Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects